HOOKIPA Pharma (HOOK) said Thursday it struck a deal to sell its key assets from its HB-400 program for hepatitis B virus and HB-500 program for human immunodeficiency virus program to Gilead Sciences (GILD) for up to $10 million.

These programs are currently in clinical development, the company said in a regulatory filing. Gilead will not acquire other assets, including its HB-500 phase 1b clinical trial.

HOOKIPA said it will receive $3 million upfront at closing, with up to $7 million due in three phases.

Shares of HOOKIPA rose past 11% in recent trading.

Price: 1.72, Change: +0.20, Percent Change: +13.16